Exelixis (EXEL) Receivables (2012 - 2026)
Exelixis (EXEL) recorded quarterly Receivables of $328.9 million in Q2 2026, up 14.65% quarter-over-quarter from $286.9 million in Q1 2026, and up 16.66% on a YoY basis from $282.0 million in Q2 2025.
Exelixis (EXEL) Receivables (2012 - 2026) Analysis & Trends
Exelixis' Receivables history runs 15 years deep, the most recent figure standing at $328.9 million for Q2 2026.
- In Q2 2026, Receivables rose 16.66% year-over-year to $328.9 million; the TTM figure through Apr 2026 stood at $328.9 million (up 16.66% YoY), while the FY2026 annual figure was $286.9 million, up 7.94% from the prior year.
- Receivables was $328.9 million for Q2 2026 at Exelixis, up from $286.9 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $398.1 million in Q2 2024 to a low of $193.8 million in Q2 2022.
- Historically, Receivables has averaged $264.5 million across 5 years, with a median of $248.7 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Receivables surged 70.05% in 2024, then slipped 26.17% in 2025.
- A 5-year view of Receivables shows it stood at $216.4 million in 2022, then rose by 10.3% to $238.7 million in 2023, then grew by 13.09% to $270.0 million in 2024, then climbed by 15.3% to $311.3 million in 2025, then gained by 5.67% to $328.9 million in 2026.
- The last three Receivables figures came in at $328.9 million (Q2 2026), $286.9 million (Q1 2026), and $311.3 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 328.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 328.95 Mn |
| Jan 2, 2026 | 286.92 Mn |
| Oct 3, 2025 | 311.30 Mn |
| Jul 4, 2025 | 293.88 Mn |
| Apr 4, 2025 | 281.96 Mn |
| Jan 3, 2025 | 265.81 Mn |
| Sep 27, 2024 | 269.98 Mn |
| Jun 28, 2024 | 398.05 Mn |
| Mar 29, 2024 | 241.92 Mn |
| Dec 29, 2023 | 238.73 Mn |
| Sep 29, 2023 | 248.75 Mn |
| Jun 30, 2023 | 234.07 Mn |
| Mar 31, 2023 | 235.31 Mn |
| Dec 30, 2022 | 216.44 Mn |
| Sep 30, 2022 | 215.38 Mn |
| Jul 1, 2022 | 235.79 Mn |
| Apr 1, 2022 | 193.85 Mn |
| Dec 31, 2021 | 284.32 Mn |
| Oct 1, 2021 | 179.49 Mn |
| Jul 2, 2021 | 182.45 Mn |